Samsonite International S.A.

1910.HK Q3 2025

Reported: 2025-11-14

Samsonite Group displayed strong momentum in Q3 2025 with a notable sequential recovery in net sales across all regions, despite ongoing challenges in North America.

Key takeaways

Q3 net sales declined just 1.3% year-over-year, a significant improvement from the 5.8% decline in Q2, indicating positive growth trends.
Direct-to-consumer sales grew by 3.5%, with e-commerce sales surging over 10%, reflecting the company's successful shift towards a more robust DTC strategy.
Gross margins expanded to 59.6%, up 30 basis points year-over-year and 60 basis points sequentially, showcasing effective management of tariff impacts.
The TUMI brand turned positive with 5% growth in Q3, driven by strong performance in Asia and Europe, while American Tourister also showed recovery with 3% growth in key markets.
Positive trends in travel and non-travel sales set an optimistic outlook for Q4, with strong early signs for holiday season performance.

View recap

Aqua Metals, Inc.

AQMS Q3 2025

Reported: 2025-11-14

Aqua Metals reported significant advancements in Q3 2025, including a successful capital raise of $17.1 million and continued progress in its lithium recycling technology, positioning itself favorably for future commercialization.

Key takeaways

Raised $17.1 million to enhance strategic flexibility and commercial planning amid a strong operational momentum.
Successfully processed lithium iron phosphate (LFP) scrap, achieving battery-grade lithium carbonate production at a pilot scale, validated by third-party testing.
Entered MOUs with Moby Robotics and Impossible Metals, expanding into deep-sea mineral feedstocks for critical metals.
Regained compliance with Nasdaq listing requirements, further solidifying the company's market position.
Year-to-date net loss improved by over 33%, showcasing effective cost management and disciplined operational practices.

View recap

Aterian, Inc.

ATER Q3 2025

Reported: 2025-11-14

Aterian, Inc. reported a Q3 2025 net revenue of $19 million, reflecting a minor sequential decline but a marked year-over-year decrease as the company navigates challenging tariff impacts and reduced consumer spending.

Key takeaways

Net revenue experienced a 2% decrease from Q2 2025; however, this marks a significant decline compared to Q3 2024, attributed to strategic price increases and decreased consumer demand.
Contribution margin improved by over 700 basis points from the previous quarter, indicating effective cost management.
Adjusted EBITDA loss improved by over 80% compared to Q2 2025, showcasing the company's progress in rationalizing fixed costs and aligning marketing strategies.
Ongoing headwinds from tariffs and competitive pricing pressure, particularly in humidifiers and steam mops, continue to challenge sales velocity.
The company has secured approximately $5.5 million in annualized savings from cost reduction initiatives, primarily through headcount reductions and vendor savings.

View recap

Bayer Aktiengesellschaft

BAYN.DE Q3 2025

Reported: 2025-11-14

The company reported a slight increase in sales and a 7% year-over-year gain in core EPS to EUR 4.29, while navigating challenges in Consumer Health and ongoing regulatory effects in Crop Science.

Key takeaways

Core EPS increased by 7% year-over-year to EUR 4.29, reflecting operational efficiency gains.
While Crop Science showed resilience with a 9% growth in corn sales, regulatory effects have led to a 2% decline in the Core Crop Protection business.
Pharmaceuticals segment propelled by strong sales of Nubeqa and Kerendia, up 60% and 80% respectively, despite pressures on Eylea.
Anticipate challenges in Consumer Health, revising full-year sales growth expectations downward due to a soft market environment.
FDA approval for Lynkuet and progress in cell and gene therapies indicate ongoing commitment to innovation and future growth prospects.

View recap

BioAtla, Inc.

BCAB Q3 2025

Reported: 2025-11-14

BioAtla, Inc. reported strong progress in its Q3 2025 earnings, achieving crucial FDA alignment for a phase three trial in oropharyngeal squamous cell carcinoma and setting the stage for a strategic partnership by year-end.

Key takeaways

Secured FDA agreement on the phase three OSV trial design for OPSCC, enabling potential accelerated and full approval.
Presentation of promising interim data for the dual CAB EpCAM TCE (BA 3182) at ESMO enhances commercial and therapeutic confidence.
Significant market opportunity for the OSFI program estimated at $800 million in peak sales for OPSCC, with broader HPV-positive solid tumors exceeding $7 billion globally.
Development milestone achieved with Context Therapeutics underlines the CAB T cell engager platform's potential and provides non-dilutive capital.
OSFI demonstrates compelling activity in heavily pretreated patients, marking a significant advancement in current treatment options.

View recap

BioCardia, Inc.

BCDA Q3 2025

Reported: 2025-11-14

BioCardia delivered solid progress in Q3, advancing its innovative cardiac therapies and engaging in constructive regulatory discussions that may accelerate market entries in both the U.S. and Japan.

Key takeaways

Received FDA breakthrough designation for CardiAmp therapy, aimed at treating ischemic heart failure, enhancing its expeditious approval pathway.
Demonstrated strong preliminary results from the chronic myocardial ischemia trial, with 60% of patients showing significant improvements in exercise tolerance and angina reduction.
Actively enrolling in the CardioAmp HF2 Phase III trial, with centers reporting rapid patient recruitment and anticipated reimbursements from CMS for both treated and control groups.

View recap

Brookfield Corporation Class A Limited Voting Shares

BN Q3 2025

Reported: 2025-11-14

Brookfield Corporation posted robust Q3 2025 results with distributable earnings of $1.3 billion, reflecting an 18% year-over-year increase, supported by strong momentum in its Wealth Solutions business and strategic investments in infrastructure.

Key takeaways

Distributable earnings before realizations reached $1.3 billion ($0.56 per share), up 18% year-over-year.
Closed $75 billion in asset sales and financed $140 billion in debt this year, capitalizing on favorable market conditions.
Acquired 100% ownership of Oaktree and advanced growth initiatives in the U.K. retirement market and Japanese insurance sector.
Positioned with almost $180 billion in deployable capital, targeting multi-decade opportunities in AI, infrastructure, and real estate.
Strategic partnerships in energy transition projects highlight Brookfield's commitment to infrastructure growth, including significant nuclear and power generation initiatives.

View recap

Bionano Genomics, Inc.

BNGO Q3 2025

Reported: 2025-11-14

Bionano reported a strong third quarter in 2025, achieving $7.4 million in revenue, representing a 21% year-over-year increase, driven by higher utilization among routine users of its optical genome mapping solutions.

Key takeaways

Total revenue rose 21% year-over-year, with core revenues up 12% after adjusting for discontinued services.
Non-GAAP gross margin improved significantly to 46%, up from 26% in Q3 2024.
Non-GAAP operating expenses decreased 40% year-over-year to $9.7 million, showcasing effective cost management.
Sold a record 8,390 flow cells, reflecting 7% growth and increased utilization by existing customers.
Cash position strengthened to $31.8 million following a $10 million public offering, extending the cash runway into 2026.

View recap

Brenntag SE

BNR.DE Q3 2025

Reported: 2025-11-14

Brenntag SE's Q3 2025 performance reflects resilience amid challenging market conditions, with a focus on enhancing sales and operational efficiency under new CEO Jens Birgersson’s leadership.

Key takeaways

Implementing immediate sales focus to strengthen customer relationships and drive revenue, rather than waiting for market recovery.
Decision-making processes are being streamlined by removing bureaucratic layers to enhance responsiveness and efficiency.
Emphasis on executing cost reduction initiatives to align the cost structure with current market realities and boost competitiveness.

View recap

Blaize Holdings, Inc.

BZAI Q3 2025

Reported: 2025-11-14

Blaize Holdings, Inc. reported a remarkable 499% revenue increase to $11.9 million in Q3 2025, driven by strategic partnerships and a $30 million investment to enhance its AI commercialization efforts.

Key takeaways

Revenue of $11.9 million reflects significant growth and is projected to double in Q4 2025.
Secured a $30 million investment from Polar Asset Management Partners to accelerate commercialization and chip development.
Established two key partnerships, including collaborations with Technology Control Company and Reach Digital, enhancing market presence.
Advanced the launch of practical AI solutions in sectors like smart infrastructure and public safety, reinforcing a shift towards efficient and deployable AI technologies.

View recap

Cellectar Biosciences, Inc.

CLRB Q3 2025

Reported: 2025-11-14

Cellectar Biosciences, Inc. reported a strong third quarter in 2025, bolstered by advances in regulatory strategies for its lead asset, iopofosine I-131, and significant progress in its clinical pipelines.

Key takeaways

Received confirmation from the EMA for conditional marketing authorization eligibility for iopofosine I-131, positioning the drug for potential EU approval as early as 2027.
Plans to submit a New Drug Application (NDA) to the FDA under the accelerated approval pathway, following favorable twelve-month follow-up data from the Clover Wham study.
Successfully raised approximately $12.7 million in recent financing to strengthen the balance sheet and support ongoing trial initiatives.
Progressed in early-phase studies of next-generation radiopharmaceuticals CLR125 and CLR225, targeting various solid tumors, with notable presentations at major cancer research conferences.
Enhanced strategic partnerships discussions aimed at expediting commercialization and securing non-dilutive capital for iopofosine I-131.

View recap

CIM Commercial Trust Corporation

CMCT Q3 2025

Reported: 2025-11-14

Creative Media & Community Trust Corporation reported a challenging third quarter with core FFO of negative $10.5 million, attributed to lower net operating income across its hotel and office segments. However, strategic asset sales and refinancing efforts have positioned the company for future growth.

Key takeaways

Completed agreement to sell non-core lending business for approximately $44 million, expected to yield net proceeds of about $31 million.
Core FFO of negative $10.5 million; net operating income declined to $7 million, down from $9.8 million in Q2.
Multifamily NOI increased by $600,000, supported by improved occupancy and reduced real estate tax expenses.
Positive trends anticipated ahead, including increased office leasing activity and improvements in hotel renovation outcomes.
Transition in CFO management expected to be seamless as Barry Neil Berlin steps down amidst company restructuring.

View recap

Inmobiliaria Colonial, SOCIMI, S.A.

COL.MC Q3 2025

Reported: 2025-11-14

Inmobiliaria Colonial SFL delivered robust earnings growth in Q3 2025, highlighted by a 5% increase in gross rental income and a strong EPRA EPS of EUR 0.25, sustaining its strategic advantage in the prime asset market.

Key takeaways

Gross rental income reached EUR 296 million, reflecting 5% like-for-like growth well above inflation.
EPRA earnings increased by 6% year-on-year, supported by strong operational performance and successful project deliveries.
Rental growth dynamics showed 9% in Paris, with overall occupancy at 91% and potential improvement to 95% with completed asset deliveries.
Maintained strong credit ratings (BBB+ from S&P, Baa1 from Moody's) and competitive debt costs with a loan-to-value ratio of 38%.
Substantial liquidity of EUR 2.8 billion, enabling effective management of upcoming debt maturities.

View recap

Circle Internet Group

CRCL Q3 2025

Reported: 2025-11-14

Circle Internet Group reported strong Q3 2025 results, characterized by significant growth in both revenue and USDC circulation, reflecting its expanding market share in the stablecoin landscape.

Key takeaways

Total revenue increased 66% year-over-year to $740 million, with adjusted EBITDA up 78% to $166 million and a robust 57% margin.
USDC in circulation surged 108% year-over-year, reaching $73.7 billion, while on-chain transactions using USDC grew 580% to $9.6 trillion.
Circle successfully launched Arc into public testnet and is exploring the launch of a native token to enhance utility and governance.
The company expanded its stablecoin network with five new chain launches, supporting a total of 28 chains, and captured a 29% market share in the stablecoin sector.

View recap

Dare Bioscience, Inc.

DARE Q3 2025

Reported: 2025-11-14

Daré Bioscience demonstrated strong momentum in Q3 2025, advancing its dual path strategy in women's health while gearing up for the launch of its sildenafil cream, DARE to PLAY, through 503B compounding.

Key takeaways

Anticipated launch of DARE to PLAY Sildenafil Cream by December 2025 marks a significant milestone in women's sexual health, utilizing a 503B outsourcing facility.
Ongoing advancement of clinical programs supported by grant funding, targeting key areas such as contraception and HPV, broadens the company’s innovation pipeline.
Strategy focuses on bridging gaps in women's health by leveraging partnerships and non-dilutive capital, enhancing market reach and operational efficiency.
CEO Sabrina Johnson emphasized the importance of addressing real-world needs and accelerating the transition from discovery to product availability for women's health solutions.

View recap

DLocal Limited Class A Common Shares

DLO Q3 2025

Reported: 2025-11-14

dLocal reported a record Q3 2025 with Total Payment Volume (TPV) exceeding $10 billion and gross profit surpassing $100 million, reflecting robust growth and strategic diversification across emerging markets.

Key takeaways

TPV grew nearly 60% YoY, marking the fourth consecutive quarter of growth above 50%, driven by strong performance in Brazil and Colombia.
Gross profit increased by 32% YoY, reaching $103 million, supported by solid volume growth despite challenges in Argentina and Mexico.
Adjusted EBITDA stood at $72 million, representing a healthy 70% of gross profit, with net income benefiting from lower finance costs linked to reduced exposure to Argentine peso bonds.
Net Revenue Retention (NRR) surged to 149%, indicating strong customer loyalty and ongoing upsell opportunities within the existing merchant base.
Continued investment in emerging payment solutions, including Buy Now, Pay Later and crypto corridors, positions dLocal as a leader in simplifying financial infrastructure for merchants across over 40 markets.

View recap

Draganfly Inc. Common Shares

DPRO Q3 2025

Reported: 2025-11-14

Draganfly reported a 14.4% year-over-year revenue increase to $2.155 million in Q3 2025, driven by strong product sales and strategic advancements in military drone applications.

Key takeaways

Launched the Outrider Southern Border drone, aimed at enhancing border security operations, with live missions commencing next week.
Strengthened military capabilities with the appointment of experienced defense leaders to the advisory board, enhancing operational sales support.
Established a partnership with Drone Nerds to distribute NDAA-compliant drones for public safety and military applications, enhancing market reach.
Secured collaborative opportunities with Global Ordinance and Autonomy Labs, further integrating innovative payload and drone technologies.
Maintained a healthy cash balance of approximately $70 million, positioning the company well for future growth initiatives.

View recap

Okeanis Eco Tankers Corp.

ECO Q3 2025

Reported: 2025-11-14

Okeanis Eco Tankers reported robust Q3 2025 results with adjusted EBITDA of $45.2 million and a consistent dividend of $0.75 per share, reflecting strategic asset management amidst a seasonally low period.

Key takeaways

Achieved fleet-wide time charter equivalent of approximately $47,000 per vessel per day, with VLCCs at $46,000 and Suezmaxes at $48,000.
Declared a 14th consecutive dividend of $0.75 per share, bringing total distributions over the last year to $2.12 per share.
Successfully positioned fleet for Q4, with 80% of VLCC spot days contracted at $88,100 per day, indicating strong future earnings potential.
Fleet utilization remained near perfect, significantly outpacing peers with performance improvements of 30% for VLCCs and 45% for Suezmaxes.
Maintained a strong balance sheet with $58 million in cash and improved refinancing terms, enhancing operational flexibility and cost efficiency.

View recap

Edible Garden AG Incorporated Common Stock

EDBL Q3 2025

Reported: 2025-11-14

Edible Garden AG Incorporated reported a 9% year-over-year revenue increase for Q3 2025, driven by expansion in their consumer packaged goods segment and operational realignment following strategic asset acquisitions.

Key takeaways

Successfully executed strategic transition towards a consumer packaged goods model, enhancing product diversity and margins.
Expanded retail partnerships, including launches in Kroger and The Fresh Market, boosting brand visibility and consumer engagement.
Continued growth of the CPG portfolio, with brands like Kick Sports Nutrition and Vitamin Whey gaining traction among health-conscious consumers.
Anticipated rise in global demand for functional foods presents a substantial growth opportunity, reinforcing the company's strategic direction.

View recap

Element Fleet Management Corp.

EFN.TO Q3 2025

Reported: 2025-11-14

Element Fleet Management achieved robust Q3 2025 results with double-digit growth in net revenue and record performance across key financial metrics, highlighting effective execution of its strategic initiatives.

Key takeaways

Net revenue reached $306 million, a 10% year-over-year increase, driven by strong service and financing revenues.
Adjusted operating income, earnings per share, and free cash flow per share all demonstrated double-digit growth.
New client acquisitions remained strong with 38 new clients added and 278 new service enrollments, enhancing share of wallet.
The launch of the Element mobile app and advances in the digital ordering platform mark significant progress in improving client experience.
An adjusted return on equity of 18.8% signifies effective capital management, with $61 million returned to shareholders through dividends and share buybacks.

View recap

Companhia Paranaense de Energia - COPEL

ELP Q3 2025

Reported: 2025-11-14

Companhia Paranaense de Energia COPEL reported a solid financial performance for Q3 2025, showcasing a recurring EBITDA increase of 7.8% to BRL 1.3 billion and a recurring net income of BRL 375 million, underpinned by strategic asset consolidation and disciplined capital allocation.

Key takeaways

Completed significant investments of BRL 981 million in CapEx during Q3, totaling BRL 2.6 billion for the year, enhancing service quality and ensuring readiness for 2026 tariff reviews.
Successfully divested four solar plants for BRL 78 million and finalized the Mashigua Sue HPP divestment, achieving a net debt-to-EBITDA ratio of 2.8x and reinforcing an optimal capital structure.
Recorded nearly 5 gigawatts in sales, with a 1.7% growth in the distribution market, reflecting resilience and customer trust despite challenging conditions.
EBITDA performance driven by the consolidation of strategic assets, including Mata de Santa Genebra, leading to increased operational efficiency across all business segments.
Preparations for migrating to Novo Mercado are advancing, aimed at simplifying shareholder structure and enhancing liquidity for attracting new investors.

View recap

Companhia Paranaense de Energia

ELPC Q3 2025

Reported: 2025-11-14

Companhia Paranaense de Energia (COPEL) demonstrated solid performance in Q3 2025 with recurring EBITDA rising to BRL 1.3 billion, reflecting an 8% year-over-year increase, while strategic divestments and investments set the stage for future growth.

Key takeaways

Recurring net income reached BRL 375 million, showcasing consistent profitability amid a challenging operational backdrop.
CapEx in Q3 totaled BRL 981 million, part of a BRL 2.6 billion investment for the first nine months, emphasizing commitment to service expansion and asset modernization.
Successful divestments, including the sale of 22 MW solar plants for BRL 78 million, align with COPEL’s strategy to optimize its portfolio and leverage capital structure, now at a healthy 2.8x net debt/EBITDA.
Sales volume approached 5 GWh with a 1.7% growth in the distribution market, demonstrating resilience and customer trust in COPEL's service.
Preparations to migrate to the Novo Mercado are progressing, with a significant shareholder vote scheduled, aimed at enhancing transparency and attracting new investors.

View recap

Hellenic Petroleum S.A.

ELPE.AT Q3 2025

Reported: 2025-11-14

HELLENiQ ENERGY Holdings reported robust Q3 2025 results, driven by strong refining margins and increased demand, achieving an adjusted EBITDA of EUR 365 million for the quarter, positioning the company on a trajectory to exceed EUR 1 billion for the year.

Key takeaways

Refining margins benefited from low commodity prices and a supply-led product shortage, supporting healthy operational performance.
The consolidated operations of Enerwave contributed significantly, marking a record for the marketing segment in Greece and internationally.
A strong interim dividend of EUR 0.20 per share indicates management's confidence in the company’s outlook.
The upcoming Thessaloniki-Skopje pipeline and growth in the green utility segment signal a strategic expansion into new markets.
Successful participation in joint ventures with ExxonMobil and Chevron boosts HELLENiQ’s credibility in offshore exploration and enhances its E&P portfolio.

View recap

PT XL Axiata Tbk

EXCL.JK Q3 2025

Reported: 2025-11-14

XLSMART reported robust growth in its first full quarter post-merger, achieving a 38% year-over-year revenue increase alongside significant operational synergies and network improvements.

Key takeaways

Revenue growth of 38% YoY and 9% QoQ driven by strong subscriber quality and improving ARPU.
Successful national roaming integration enhances service quality for Smartfren customers and boosts coverage by 38%.
On track to achieve $150-$200 million in synergies for FY 2025, with long-term targets of $300-$400 million pretax.
Mobile, Enterprise, and Home segments each driving distinct growth opportunities across diverse customer needs.
Customer engagement initiatives and improved network performance leading to increased user satisfaction and retention.

View recap

FitLife Brands, Inc.

FTLF Q3 2025

Reported: 2025-11-14

FitLife Brands reported a robust 47% year-over-year revenue increase in Q3 2025, driven significantly by the recent acquisition of Irwin Naturals, although gross margins faced pressure from increased costs and the integration of the new brand.

Key takeaways

Total revenue reached $23.5 million, with Irwin Naturals contributing $6.8 million despite only 53 days of operations.
Legacy FitLife's organic growth was 8% excluding MRC, while MusclePharm delivered an impressive 55% organic growth, driven by a 112% increase in wholesale revenue.
Gross margin declined to 37.2%, reflecting lower margins in the MusclePharm brand and the impact of Irwin, though adjusted gross margin was more favorable at 38.9% excluding inventory step-up amortization.
Net income fell to $0.9 million, impacted by acquisition-related expenses and a higher effective tax rate.
Wholesale revenue soared by 156% year-over-year, indicating strong distribution channels and potential for continued growth post-acquisition.

View recap

Grove Collaborative Holdings, Inc.

GROV Q3 2025

Reported: 2025-11-14

Grove Collaborative reported a challenging third quarter with revenue down 9.4% year-over-year amidst ongoing platform migration issues, yet demonstrated improved customer experience resilience and focused on long-term profitability.

Key takeaways

Revenue declined 9.4% year-over-year but was nearly flat quarter-over-quarter, marking the smallest decrease since Q3 2021.
Completed a restructuring that included a reduction in force, expected to yield $5 million in annualized savings, enhancing cost-efficiency.
Expansion of third-party brands and products up 50% and 61% respectively, particularly in clean beauty, personal care, and baby categories.
Ongoing focus on improving the mobile app and subscription experiences to drive customer engagement and retention.
Evaluating strategic opportunities for acquisitions or partnerships to accelerate growth while maintaining a commitment to profitability and sustainability.

View recap

Fractyl Health, Inc. Common Stock

GUTS Q3 2025

Reported: 2025-11-14

Fractyl Health achieved a significant milestone in Q3 2025 by demonstrating the efficacy of its Revita procedure in maintaining weight loss after the discontinuation of GLP-1 therapy, while also strengthening its financial position for upcoming clinical milestones.

Key takeaways

Successfully reported randomized double-blind data indicating sustained weight loss in Revita-treated patients post-GLP-1 therapy, a critical advancement in obesity treatment.
Clinical programs are ahead of schedule, with over 60% of patient randomizations for the pivotal REMAIN one cohort completed.
Upcoming catalysts include six-month data from multiple cohorts and pivotal study results expected in 2026, positioning Revita for potential transformative impact in metabolic medicine.
Real-world studies further validate Revita's efficacy, showing significant weight loss and reductions in HbA1c in patients with type 2 diabetes over extended follow-up periods.

View recap

ESS Tech Inc. Common Stock

GWH Q3 2025

Reported: 2025-11-14

ESS Tech, Inc. reported a significant shift toward its energy-based platform, with a major pilot project announced alongside an important capital raise, setting the stage for future growth.

Key takeaways

Revenue for Q3 2025 was $200,000, down from $2.4 million in Q2, reflecting the transition to the new energy-based platform.
Successfully secured a 50 MWh pilot project with Salt River Project, marking the first commercial deployment of the new technology.
Completed a $40 million financing with Yorkville Advisors, enhancing financial stability and paving the way for upcoming manufacturing and project execution.
Launched a $75 million at-the-market equity program to support future growth and operational needs efficiently.
100% of active business opportunities now center around the energy-based platform, indicating strong market interest and alignment with strategic goals.

View recap

Humacyte Inc. Common Stock

HUMA Q3 2025

Reported: 2025-11-14

Humacyte delivered strong third-quarter results, with significant sales growth for its bioengineered vascular product, Symvess, and successful advancement in clinical studies supporting its commercial strategy.

Key takeaways

Product sales reached $703,000, up from $100,000 in the previous quarter, demonstrating robust traction in the market.
Symvess received approvals from Value Analysis Committees representing 92 hospitals, with 45 additional committees currently reviewing the product.
The company has successfully made its first sales to U.S. military facilities following its Electronic Catalog listing by the Defense Logistics Agency.
Recent clinical publications highlight the effectiveness and safety of Symvess in treating vascular trauma, with impressive long-term outcomes reported.
The company continues to engage actively with surgeons and healthcare systems, increasing order placements and product reorders.

View recap

Hyperfine Inc. Class A Common Stock

HYPR Q3 2025

Reported: 2025-11-14

Hyperfine, Inc. reported a strong Q3 2025, with a 27% sequential revenue increase driven by the successful launch of its next-generation MRI subsystem and Optive AI software, resulting in a substantial improvement in gross margins.

Key takeaways

Revenue reached $3.4 million, up 27% sequentially, with gross margins expanding to nearly 54%.
Cash burn reduced by 27% sequentially, and over $20 million raised to extend the company’s cash runway into 2027.
Strong market demand for the next-generation subsystem, leading to robust sales funnel activation across diversified commercial verticals including hospitals and office settings.
Positive user feedback on image quality, positioning Hyperfine for broader adoption in both domestic and international markets.
The company plans to release software upgrades to enhance functionality on a regular basis, underscoring a commitment to continuous innovation.

View recap

Imunon Inc. Common Stock

IMNN Q3 2025

Reported: 2025-11-14

Imunon reported strong momentum in its pivotal OVATION 3 trial for IMNN-001, showcasing unprecedented overall survival benefits and a robust strategy for expanding trial sites and patient enrollment.

Key takeaways

Successful R&D day highlighted IMNN-001's transformative potential, emphasizing a 13-month median survival benefit in advanced ovarian cancer.
OVATION 3 trial enrollment surpassed internal targets, achieving nine randomized patients by October 2025, with plans to activate additional sites before year-end.
FDA endorsement of overall survival as the primary endpoint positions Imunon favorably for regulatory approval in both the U.S. and Europe.

View recap

MiNK Therapeutics Inc. Common Stock

INKT Q3 2025

Reported: 2025-11-14

MiNK Therapeutics achieved significant clinical milestones in Q3 2025, demonstrating promising survival outcomes for patients with relapsed or refractory cancers through its investigational AGENT-797 therapy, while strengthening collaborations and enhancing its operational independence.

Key takeaways

AGENT-797 therapy demonstrated a remarkable median overall survival of approximately 23 months in patients treated for resistant solid tumors, far exceeding expectations for this patient cohort.
The therapy exhibited a strong safety profile, with no major toxicities observed, underscoring its potential as a viable treatment option in challenging cancer cases.
MiNK has established strategic partnerships with the University of Wisconsin and received significant funding support for advancing its iNKT cell therapy platform, aimed at improving outcomes post-stem cell transplantation.
The company's leadership was strengthened with the appointment of Dr. John Holcomb to the Board, enhancing its strategic vision in clinical development and partnerships.
MiNK Therapeutics is positioned as a leader in the allogeneic iNKT cell space, bolstered by its scientific advancements and disciplined capital utilization.

View recap

Ideal Power Inc.

IPWR Q3 2025

Reported: 2025-11-14

Ideal Power's third quarter 2025 results showcase strategic momentum with key customer engagements and a new CEO focused on accelerating revenue growth in high-potential markets.

Key takeaways

Secured a significant purchase order from Stellantis for custom B-TRAN devices aimed at multiple EV applications, with the first milestone completed.
Anticipate a multiyear EV contactor program with Stellantis, potentially deploying B-TRAN technology in test vehicles by late 2026.
Engaged in preliminary discussions with a sixth global automaker for next-generation high-voltage EV applications using B-TRAN.
Successfully completed tests with a design win customer on updated solid-state circuit breakers, moving towards final product design and sampling.
Continued shipment of solid-state circuit breaker reference designs to major global players, enhancing commercialization efforts for B-TRAN technology.

View recap

Iterum Therapeutics plc

ITRM Q3 2025

Reported: 2025-11-14

Iterum Therapeutics reported steady initial progress in the commercialization of Orlynda, with early prescriptions showing positive traction among prescribers despite ongoing payer coverage challenges.

Key takeaways

Over 280 prescriptions for Orlynda generated within the early weeks post-launch, with over 100 unique prescribers.
Around 40% of prescriptions have been filled through specialty pharmacy partners, indicating initial acceptance despite limited payer decisions.
Collaboration with major distributors McKesson and AmerisourceBergen underway to enhance accessibility for prescribers outside typical purchasing models.
Positive feedback from physicians highlights Orlynda's potential to treat uncomplicated urinary tract infections effectively, especially in cases of antibiotic resistance.

View recap

IZEA Worldwide, Inc.

IZEA Q3 2025

Reported: 2025-11-14

IZEA Worldwide, Inc. reported a strategic shift towards higher quality enterprise accounts, achieving net income of $100,000 for Q3 2025, marking three consecutive quarters of profitability despite an 8% decline in total revenue.

Key takeaways

Managed services revenue, excluding Hozoo, rose 5%, indicating strong growth in targeted enterprise clients.
Total operating expenses decreased by 67%, reflecting improved cost management and operational efficiency.
Net income for the quarter reached $100,000 compared to a net loss of $8.8 million in Q3 2024, reinforcing the company’s profitable trajectory.
Cash reserves increased by $800,000 to $51.4 million, bolstering financial stability.
Investments in technology and new leadership in account management aim to enhance enterprise growth and client servicing capabilities.

View recap

JD.com, Inc.

JD Q3 2025

Reported: 2025-11-14

JD.com demonstrated robust Q3 2025 performance, achieving a 15% rise in total revenues year-on-year while expanding its active customer base significantly.

Key takeaways

Quarterly active customer count rose over 40% year-on-year, surpassing 700 million, with strong growth in JD Plus membership.
Core retail revenues increased by 11% to RMB 251 billion, boosted by exceptional growth in the general merchandise category (19% year-on-year).
Marketplace and marketing revenues surged 24% year-on-year, marking four consecutive quarters of double-digit growth, driven by enhanced advertising efficiency.
JD Food Delivery showed double-digit quarter-on-quarter GMV growth, narrowing operating losses and reinforcing synergies with the core retail business.
Management remains optimistic about continued market share expansion and improved profitability across business segments.

View recap

Luminar Technologies, Inc.

LAZR Q3 2025

Reported: 2025-11-14

Luminar Technologies, Inc. faced significant challenges in Q3 2025, necessitating a strategic pivot towards non-automotive markets while managing ongoing capital restructuring efforts.

Key takeaways

Entered forbearance agreements with secured noteholders, leading to the suspension of 2025 financial guidance and equity financing programs.
Uncertainty with Volvo's relationship may drastically impact future revenues, influencing a shift towards aerospace and defense markets, where demand is growing.
New management appointments aim to strengthen the company's restructuring efforts and operational execution.
LSI Photonics, representing about one-third of Luminar's annual revenue, is positioned for growth, driven by increased defense budgets and national security priorities.

View recap

ReWalk Robotics Ltd.

LFWD Q3 2025

Reported: 2025-11-14

Lifeward Ltd. achieved a modest revenue increase in Q3 2025, with significant operational improvements reflected in reduced cash burn and operating losses, indicating a focused transformation underway.

Key takeaways

Quarterly revenue rose 8% sequentially to $6.2 million, driven by record ReWalk placements for Medicare beneficiaries.
Non-GAAP operating loss decreased by 27% year-over-year, signaling improved operational efficiency.
Established first Medicare Advantage commercial revenue and received CE Mark approval, expanding European market access.
Implemented a $3 million loan to strengthen liquidity and support the ongoing transformation plan.
Closed with over 200 systems in backlog and a healthy pipeline of qualified leads in the U.S. and Germany.

View recap

LM Funding America, Inc.

LMFA Q3 2025

Reported: 2025-11-14

LM Funding America, Inc. demonstrated significant growth in Q3 2025, bolstered by strategic acquisitions and a robust Bitcoin treasury that enhanced operational efficiency and profitability.

Key takeaways

Revenue reached $2.2 million, marking a 13% sequential increase and 74% year-over-year growth.
Bitcoin treasury grew to approximately 304.5 BTC, valued at nearly $35 million, significantly exceeding the company’s market cap.
Mining production rose 28% month-over-month to 7.6 BTC in October, driven by increased capacity from the newly acquired Mississippi facility.
The company reduced dilution by retiring 3.3 million shares and over 7.3 million warrants, enhancing Bitcoin per share.
Continued investment in advanced mining technology anticipated to drive further operational efficiency and production increases in the coming months.

View recap

Lifeway Foods, Inc.

LWAY Q3 2025

Reported: 2025-11-14

LifeWay Foods reported record-breaking third-quarter net sales of $57.1 million, representing a 24% year-over-year increase, underscoring the company's strong momentum in the functional dairy sector.

Key takeaways

Achieved 24% year-over-year growth in net sales, marking the 24th consecutive quarter of sales increases.
Gross profit margin expanded by 300 basis points to 28.7%, driven by volume growth and operational efficiencies.
Announced plans for a $45 million modernization project at the Waukesha facility, expected to double manufacturing capacity by 2026.
Launched innovative products including MuscleMase, a ready-to-drink beverage targeting the fast-growing creatine market.
Recognized in Time's America's Growth Leader 2026 list, highlighting LifeWay as the second fastest-growing food and beverage company.

View recap

NORTHLAND POWER INC

NPI.TO Q3 2025

Reported: 2025-11-14

Northland Power reported strong Q3 2025 results, underscored by high operational availability exceeding 95%, despite facing challenges in project timelines and a dividend adjustment to enhance financial flexibility.

Key takeaways

Q3 operational performance surpassed last year's results, buoyed by favorable wind conditions.
Dividend reduced to $0.72 annually to allow self-funded growth and maintain an investment-grade balance sheet.
Major construction projects, including Hai Long and Baltic Power, are on track for completion, with commercial operations expected in 2027 and late 2026, respectively.
Safety achievements highlighted by the Ontario Electrical Safety Award for the Oneida battery storage project, emphasizing Northland's commitment to safety standards.
The company is actively pursuing organic growth opportunities in core markets of Canada and Europe, with a strong pipeline of renewable and battery storage projects.

View recap

Ondas Holdings Inc.

ONDS Q3 2025

Reported: 2025-11-14

Ondas Holdings achieved robust growth in Q3 2025, reporting over a six-fold increase in revenue year-over-year and raising its full-year outlook significantly due to strong demand for its autonomous systems.

Key takeaways

Revenue surged to $10.1 million, a 60% sequential increase from Q2, driven by expanding customer pipelines in autonomous systems.
Backlog reached $23.3 million, more than doubling year-to-date, with potential growth to over $40 million when factoring in pending acquisitions.
Full-year 2025 revenue target increased to at least $36 million, with a strategic goal of reaching $110 million in 2026.
Ondas is expanding operational infrastructure to support multiyear growth, focusing on integrated autonomy systems.

View recap

Owlet, Inc.

OWLT Q3 2025

Reported: 2025-11-14

Owlet, Inc. delivered record-breaking Q3 2025 results with a 45% revenue increase year-over-year, marking its first quarterly operating profit, driven by strong demand for its new DreamSight camera and continued market momentum.

Key takeaways

Q3 revenue reached $32 million, a record high, fueled by the successful launch of the DreamSight camera.
Gross profit improved to $16.2 million, achieving a gross margin of 50.6%, despite tariff impacts.
Owlet reported its first-ever operating income of $1.2 million, highlighting sustained profitability with six consecutive quarters of adjusted EBITDA profits.
DreamSock demand in the U.S. soared, with domestic sell-through growing 42% year-over-year and contributing to a 40% market share in baby monitors.
International revenue surged by 171% year-over-year, bolstered by the launch of DreamSight and expansion in global sales channels.

View recap

PagSeguro Digital Ltd.

PAGS Q3 2025

Reported: 2025-11-14

PagSeguro Digital Ltd. demonstrated resilience in the face of a challenging macroeconomic environment, achieving solid growth with a 14% increase in net revenue while maintaining profitability and expanding its client base.

Key takeaways

Total net revenue reached BRL 3.4 billion, marking a 14% increase year over year, driven by strong operational execution.
The client base grew to 33.7 million, adding 1.6 million clients over the past year, with active banking clients rising by 2%.
Total deposits increased by 15% year over year to BRL 39.4 billion, alongside a sixth consecutive quarter of reduced funding costs.
Non-GAAP net income remained flat year on year, while GAAP diluted EPS rose by 1.814%, supported by disciplined cost management.
The company returned BRL 2 billion to shareholders through dividends and share repurchases, underscoring a strong capital allocation strategy.

View recap

Precigen, Inc.

PGEN Q3 2025

Reported: 2025-11-14

Precigen's third quarter of 2025 demonstrated a strong commercial launch of its breakthrough treatment Papcemias, which received FDA approval in August, paving the way for it to become the standard of care for recurrent respiratory papillomatosis (RRP).

Key takeaways

Papcemias achieved FDA approval with a broad label, marking it as the first and only treatment for adults with RRP.
The pivotal clinical trial results showed 51% of patients achieved a complete response with no surgery required for 12 months, and 86% experienced reduced surgical burden.
Precigen's sales team has engaged 90% of target institutions, resulting in multiple national formulary approvals and over 100 patients registered in the Precigen patient services hub.
Strong payer coverage is already in place, with over 80 million lives covered, facilitating rapid market access.

View recap

Pioneer Power Solutions, Inc.

PPSI Q3 2025

Reported: 2025-11-14

Pioneer Power Solutions, Inc. reported a strong third quarter performance with 7.4% revenue growth year-over-year, driven by increased demand for mobile charging solutions and successful project completions.

Key takeaways

Revenue for Q3 reached $6.9 million, with year-to-date revenue up 68% to $22 million, primarily from eBoost mobile charging solutions.
Significant deliveries included a $1.3 million order for a school electrification project and multiple eBoost units for the city of Portland and Long Beach.
Strategic expansion into the distributed power market generated over $700,000 in deliveries and $750,000 in new orders across various sectors, indicating strong market demand.
PowerCore, formerly HomeBoost, is set to launch in December, enhancing offering appeal to both residential and light commercial markets.
Ongoing partnership with a major online retailer positions Pioneer for further growth in the eBoost segment in 2026.

View recap

Paysafe Limited

PSFE Q3 2025

Reported: 2025-11-14

Paysafe reported strong third-quarter results with 6% organic revenue growth, bolstered by a 37% increase in adjusted EPS, underscoring effective client acquisition and solid performance across core markets.

Key takeaways

Achieved 6% organic revenue growth and 7% adjusted EBITDA growth in Q3 2025.
Notable strength in North America, driven by a 50% growth in iGaming, along with client wins such as BetMGM.
Continued share repurchase initiative with an additional $70 million authorized, reflecting confidence in long-term strategy.
E-commerce growth exceeded 20%, underpinned by a substantial rise in enterprise-level deals and improving revenue per merchant.
Outlook adjusted for extended timelines on key product initiatives, signaling ongoing adaptation to market dynamics.

View recap

Red Cat Holdings, Inc.

RCAT Q3 2025

Reported: 2025-11-14

Red Cat achieved record revenues of $9.6 million in Q3 2025, representing a 200% increase from the previous quarter, driven by heightened demand for drone and robotic solutions in the defense sector.

Key takeaways

Expansion of the limited-rate initial production contract for the Black Widow system to $35.1 million underscores confidence in Red Cat's technologies.
Launch of the new Blue Ops maritime division opens substantial revenue potential with a production facility capable of 500-1,000 vessels annually.
Continued momentum with U.S. Army contracts, though full-year revenue guidance adjusted to $34.5 million - $37.5 million due to delays, reflects strong future prospects.
Successful integration of Palantir's Visual Navigation software enhances operational capabilities in complex environments, driving potential margin improvements.

View recap

Banco de Sabadell, S.A.

SAB.MC Q3 2025

Reported: 2025-11-14

Sabadell reported solid third-quarter results, achieving a recurrent return on tangible equity of 14.1% while maintaining strong growth in performing loans and customer funds, positioning the bank well to meet its 2025 financial targets.

Key takeaways

Return on tangible equity rose to 14.1%, with a target of 16% by 2027, reaffirming the bank's strong profitability trajectory.
Customer funds grew by 7.8% year-on-year, driven primarily by off-balance sheet products, indicating robust commercial activity.
Confirmation of a second interim cash dividend of EUR 0.07 per share, part of a total EUR 1.45 billion distribution for 2025.
Core revenues are on track with net interest income expected to meet the EUR 3.6 billion target for 2025.
Asset quality improved, with total cost of risk down to 37 basis points, showcasing strong credit management practices.

View recap

Similarweb Ltd.

SMWB Q3 2025

Reported: 2025-11-14

Similarweb reported solid Q3 results with an 11% year-over-year revenue increase to $72 million, driven by a growing customer base and continued success in their AI-driven products. The company remains focused on profitable growth, maintaining positive free cash flow for the eighth consecutive quarter.

Key takeaways

Customer base expanded by 15% year-over-year, exceeding 6,000 ARR customers.
Achieved $3 million in normalized free cash flow, marking a 4% free cash flow margin.
Revenue from the Gen AI Intelligence product exceeded $1 million in ARR since its launch in April.
Reiterated 2025 revenue guidance at $285 million to $288 million, with an increase in non-GAAP operating profit guidance to $8.5 million - $9.5 million.
Notable growth in multi-year contracts, contributing to 58% of ARR, up from 45% last year.

View recap

Sow Good Inc.

SOWG Q3 2025

Reported: 2025-11-14

Sow Good Inc. reported a challenging Q3 2025, with revenues falling to $1.6 million as the company executed a strategic overhaul aimed at long-term profitability while incurring higher operational costs due to discontinued product lines.

Key takeaways

Revenue decreased significantly to $1.6 million, down from $36 million in Q3 2024, primarily due to the closeout of non-performing SKUs.
Gross loss widened to $8.9 million, reflecting a negative gross margin of 576%, driven largely by non-cash inventory charges.
Operating expenses were slightly reduced to $3.7 million from $3.8 million year-over-year, showcasing improved efficiency amid restructuring efforts.
The company has secured over $5 million in annual rent savings through facility consolidations and is set to launch innovative new SKUs in 2026, including a private label partnership with a national retailer.
Insider commitments of $1 million bolster working capital and reinforce leadership confidence in the company's recovery and growth strategy.

View recap

SuperCom Ltd.

SPCB Q3 2025

Reported: 2025-11-14

SuperCom Ltd. reported strong operational momentum in Q3 2025, achieving significant contract wins in the US and international markets that underscore its competitive edge in electronic monitoring solutions.

Key takeaways

Secured over 30 new electronic monitoring contracts across 12 states in the US, including displacing legacy vendors.
Expanded international presence with a $7 million electronic monitoring project awarded in Germany.
Continued success from subsidiary Leaders in Community Alternatives, securing a five-year contract worth up to $2.5 million.
Growth in domestic violence monitoring programs, now active in nine countries globally.
Leveraging a centralized cloud-based platform to enhance operational efficiency and accelerate market penetration.

View recap

STRATA Skin Sciences, Inc.

SSKN Q3 2025

Reported: 2025-11-14

STRATA Skin Sciences reported a challenging third quarter with revenues decreasing by 20% year-over-year, largely due to international market pressures, while domestic recurring revenues demonstrate resilience and growth.

Key takeaways

Total revenue for Q3 2025 was $6.9 million, a decline of 20% compared to Q3 2024, primarily impacted by international trade uncertainties.
U.S. recurring revenue from XTRAC increased by 2.8%, signaling stability within domestic operations.
The expanded CPT codes for XTRAC treatments, effective January 2027, offer potential access to over 30 million patients, significantly enlarging the company’s market opportunity.
The Elevate360 program has driven an average clinic growth rate of 7% year-over-year and improved gross billings per device by 8.5% compared to last year.
STRATA is pursuing legal action against LaserOptik, anticipating significant damages that could bolster revenue from previously misled clinics.

View recap

Tecogen Inc.

TGEN Q3 2025

Reported: 2025-11-14

Tecogen continues to gain traction in the data center cooling market, reporting strong interest from major developers, including NVIDIA and AMD, alongside a successful validation process for their innovative chillers.

Key takeaways

Significant progress in data center strategy with interest from hyperscale developers increasing, marking a shift from initial leads from independent developers.
A notable Letter of Intent (LOI) for six STX chillers may lead to expanded sales as ongoing discussions could include multiple projects with over 200 MW capacity.
Manufacturing capacity enhancements are underway with adjustments in factory layout and partnerships with contract manufacturers, ensuring readiness to meet rising demand.

View recap

Acuren Corporation

TIC Q3 2025

Reported: 2025-11-14

TIC Solutions reported a solid Q3 2025 performance with approximately 5% year-over-year revenue growth, bolstered by strong demand in the consulting engineering segment and successful integration of Acuren and NV5.

Key takeaways

Combined revenue now exceeds $2 billion, with significant double-digit growth in the Consulting Engineering segment driven by data center projects.
Geospatial services saw mid-single-digit growth, supported by high utilization and stable demand from public and private clients.
Successful collaboration on cross-sell initiatives, including a nationwide laser scanning program and a Digital Twin project for major clients, enhances operational capabilities and client value.
The integration of services from both legacy companies is expected to generate meaningful synergies as operations streamline into 2026.
Continued investments in infrastructure and energy transition markets position TIC Solutions favorably for long-term growth.

View recap

TMC the metals company Inc.

TMC Q3 2025

Reported: 2025-11-14

TMC the metals company reported robust progress in Q3 2025, highlighting significant developments toward its U.S. pivot and regulatory applications, while maintaining a strong liquidity position.

Key takeaways

Achieved approximately $165 million in liquidity, bolstered by recent warrant exercises, with an anticipated influx of over $400 million from future warrant exercises.
Continued regulatory collaboration with NOAA indicates a clear pathway to a commercial recovery permit by 2027, contingent upon streamlined application processes.
Asserted commitment to addressing U.S. dependency on foreign metals, emphasizing the strategic importance of its resource potential in metals like manganese, cobalt, and nickel.
Announced collaboration with Allseas for nodule collection trials in Japan, enhancing technical readiness ahead of U.S. commercial production.

View recap

Tenon Medical Inc. Common Stock

TNON Q3 2025

Reported: 2025-11-14

Tenon Medical demonstrated robust growth in Q3 2025, achieving record revenues of $1.2 million, a 32% increase year-over-year, driven by high demand for its innovative sacroiliac joint fusion solutions.

Key takeaways

Successful integration of CyVantage's Symmetry portfolio contributed to top-line growth, marking a pivotal point in Tenon’s strategic expansion.
Full commercial launch of the Catamaran SE system showcased enhanced functionality, addressing varied patient needs and improving competitive positioning.
Positive clinical outcomes from the ongoing main sales study further validated the efficacy of the Catamaran system, with statistically significant improvements in patient pain and disability scores.
Tenon received FDA 510(k) clearance for the Symmetry Plus system, enhancing its product offerings and preparing for the upcoming alpha launch.
Cash position remained strong at $3.4 million with no debt, supplemented by a recent $2.85 million investment.

View recap

The Oncology Institute Inc. Common Stock

TOI Q3 2025

Reported: 2025-11-14

The Oncology Institute delivered strong third quarter results, achieving $137 million in revenue—up 23% year-over-year—while marking its first month of adjusted EBITDA profitability as a public company.

Key takeaways

Pharmacy business surged 42% year-over-year, driving significant revenue growth.
Achieved a $4.7 million improvement in adjusted EBITDA loss compared to Q3 2024, with expectations to reach overall profitability in Q4.
Expanded partnership with Elevance Health, doubling the Medicare Advantage lives under capitation in under a year.
Launched AI initiatives to enhance operational efficiency, potentially saving $2 million in operating expenses.
Despite a recent cybersecurity incident affecting billing, operations remained largely unaffected, with strong cash reserves projected for Q4 and 2026.

View recap

VI

Via Renewables, Inc.

VIA Q3 2025

Reported: 2025-11-14

Via reported a strong Q3 2025 performance with revenue growth of 32% year-over-year, driven largely by an increase in government business.

Key takeaways

Revenue grew to $439 million on an annual run rate basis, with government revenue up 34% year-over-year, contributing an additional $26.5 million.
The number of customers on the platform reached 713, an 11% increase compared to the previous year, indicating strong market penetration.
Via maintains a significant market opportunity with less than 1% capture of an estimated $82 billion serviceable addressable market in North America and Western Europe.

View recap

Westwater Resources, Inc.

WWR Q3 2025

Reported: 2025-11-14

Westwater Resources reported strategic adjustments following the termination of the Stellantis offtake agreement, focusing on optimizing production at the Kellyton Graphite Plant to align with remaining commitments and to enhance financial resilience.

Key takeaways

Stellantis unexpectedly terminated its offtake agreement, pausing debt syndication reliant on this contract.
Westwater has made significant investments of approximately $125 million in Kellyton, positioning it as the leading U.S. producer of battery-grade graphite.
The company successfully launched large sample deliveries from its qualification line, achieving over 1 metric ton production for current and potential clients.
Efforts are underway to optimize production capacity and reduce capital expenditures ahead of Phase 1 commercial production, targeted for early 2026.
Advances in the Coosa deposit permitting process are ongoing, aiming for vertical integration of graphite mining and processing.

View recap

WidePoint Corporation

WYY Q3 2025

Reported: 2025-11-14

WidePoint reported a modest revenue increase of 4% year-over-year for Q3 2025, while demonstrating a significant recovery in adjusted EBITDA and free cash flow, marking a positive turnaround in financial performance.

Key takeaways

Revenues reached $36.1 million, an increase from the prior year, while adjusted EBITDA improved to $344,000, showcasing positive momentum.
Achieved an astonishing 88,260% sequential increase in free cash flow for the quarter, reinforcing ongoing operational stability.
Secured a major multi-year SaaS contract expected to generate $40 to $45 million in revenue, validating the strategic investment in the FedRAMP authorization.
Well-positioned for upcoming DHS CWMS 3.0 contract opportunities, with proposal due on December 17, 2025, anticipating a decision in early Q2 2026.
Awarded eight task orders under Spiral 4, highlighting competitiveness within a challenging landscape and potential for future market share growth.

View recap

Xos Inc. Common Stock

XOS Q3 2025

Reported: 2025-11-14

Xos, Inc. reported robust growth in Q3 2025, achieving record vehicle shipments and demonstrating strong demand from key customers, while strategically honing its focus on profitability and product diversification.

Key takeaways

Shipped a record 130 vehicles, generating $16.5 million in revenue, with 140 total shipments including ongoing customer programs.
Achieved a GAAP gross margin of 15.3%, reflecting complex pricing dynamics but laying a foundation for future margin improvement through large fleet agreements.
Narrowed operating losses to $7 million, the lowest since going public, due to rigorous cost management and operational efficiency.
Strengthened liquidity through a revamped repayment structure with Alger Mae Automotive, enhancing operational focus and financial flexibility.
Expanded into higher-margin segments, successfully delivering 18 powertrain systems and securing nearly 80 additional orders, signaling growth in the school bus electrification market.

View recap

Earnings Recaps

Samsonite International S.A.

Aqua Metals, Inc.

Aterian, Inc.

Bayer Aktiengesellschaft

BioAtla, Inc.

BioCardia, Inc.

Brookfield Corporation Class A Limited Voting Shares

Bionano Genomics, Inc.

Brenntag SE

Blaize Holdings, Inc.

Cellectar Biosciences, Inc.

CIM Commercial Trust Corporation

Inmobiliaria Colonial, SOCIMI, S.A.

Circle Internet Group

Dare Bioscience, Inc.

DLocal Limited Class A Common Shares

Draganfly Inc. Common Shares

Okeanis Eco Tankers Corp.

Edible Garden AG Incorporated Common Stock

Element Fleet Management Corp.

Companhia Paranaense de Energia - COPEL

Companhia Paranaense de Energia

Hellenic Petroleum S.A.

PT XL Axiata Tbk

FitLife Brands, Inc.

Grove Collaborative Holdings, Inc.

Fractyl Health, Inc. Common Stock

ESS Tech Inc. Common Stock

Humacyte Inc. Common Stock

Hyperfine Inc. Class A Common Stock

Imunon Inc. Common Stock

MiNK Therapeutics Inc. Common Stock

Ideal Power Inc.

Iterum Therapeutics plc

IZEA Worldwide, Inc.

JD.com, Inc.

Luminar Technologies, Inc.

ReWalk Robotics Ltd.

LM Funding America, Inc.

Lifeway Foods, Inc.

NORTHLAND POWER INC

Ondas Holdings Inc.

Owlet, Inc.

PagSeguro Digital Ltd.

Precigen, Inc.

Pioneer Power Solutions, Inc.

Paysafe Limited

Red Cat Holdings, Inc.

Banco de Sabadell, S.A.

Similarweb Ltd.

Sow Good Inc.

SuperCom Ltd.

STRATA Skin Sciences, Inc.

Tecogen Inc.

Acuren Corporation

TMC the metals company Inc.

Tenon Medical Inc. Common Stock

The Oncology Institute Inc. Common Stock

Via Renewables, Inc.

Westwater Resources, Inc.

WidePoint Corporation

Xos Inc. Common Stock

Community

Trending This Week

Notifications